RP Management LLC:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:RP Management LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10821
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
RP Management LLC (RP Management) is a life sciences financing company that offers biopharmaceutical products. The company’s products include thalomid, myozyme, lexiscan, rituxan, atripla, lyrica, prezista, letairis, januvia, onglyza, neupogen, rotateq, cubicin, savella, and others. It also provides nesina, remicade, humira, galvus, cimzia, mircera, tradjenta, viviant, Xtandi, tecfidera, imbruvica, and priligy. RP Management has interests in approved and late stage development bio-pharmaceutical products. The company offers its products in the therapeutic areas of rheumatoid arthritis (RA), chronic kidney disease, Crohn’s disease, diabetes, HIV/AIDS and others. It operates through research institutions, biotechnology and pharmaceutical companies, and inventors. RP Management is headquartered in New York, the US.

RP Management LLC – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
RP Management LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
RP Management LLC, Medical Devices Deals, 2012 to YTD 2018 9
RP Management LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
RP Management LLC, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Royalty Pharma Acquires Royalty Streams and Milestones of Products from Zealand Pharma 11
Royalty Pharma to Acquire Royalty Rights of Sacituzumab Govitecan from Immunomedics for USD175 Million 13
Royalty Pharma Acquires Royalty Stream of Tysabri from Perrigo for USD2.85 Billion 14
Royalty Pharma Acquires Royalty Rights of Xtandi from University of California, Los Angeles for USD1.14 Billion 16
Royalty Pharma Acquires Royalties on Cystic Fibrosis Treatments from Cystic Fibrosis Foundation Therapeutics for USD3.3 Billion 18
Royalty Pharma Completes Acquisition of Royalties on Alogliptin and Priligy from Forest Labs for USD415 Million 20
Royalty Pharma Acquires Additional Stake In Tecfidera, Oral Multiple Sclerosis Drug, For US$510 Million 21
Royalty Pharma Acquires Ibrutinib Royalty Rights From Quest Diagnostics For US$485 Million 22
Royalty Pharma Completes Acquisition Of Royalty Agreement For Vosaroxin From Sunesis Pharma For US$25 Million 23
Royalty Pharma Acquires BG-12 And Fumaderm From Fumapharm For US$761 Million 25
Venture Financing 26
Avillion Secures Funds from Royalty Pharma 26
Private Equity 27
Aisling Capital And Clarus Ventures Acquire 20% Of Royalty Interest In Ibrutinib From Royalty Pharma 27
Equity Offering 28
Immunomedics to Raise USD75 Million in Private Placement of Shares 28
RP Management LLC – Key Competitors 30
RP Management LLC – Key Employees 31
RP Management LLC – Locations And Subsidiaries 32
Head Office 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
RP Management LLC, Pharmaceuticals & Healthcare, Key Facts 2
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
RP Management LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
RP Management LLC, Deals By Therapy Area, 2012 to YTD 2018 8
RP Management LLC, Medical Devices Deals, 2012 to YTD 2018 9
RP Management LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Royalty Pharma Acquires Royalty Streams and Milestones of Products from Zealand Pharma 11
Royalty Pharma to Acquire Royalty Rights of Sacituzumab Govitecan from Immunomedics for USD175 Million 13
Royalty Pharma Acquires Royalty Stream of Tysabri from Perrigo for USD2.85 Billion 14
Royalty Pharma Acquires Royalty Rights of Xtandi from University of California, Los Angeles for USD1.14 Billion 16
Royalty Pharma Acquires Royalties on Cystic Fibrosis Treatments from Cystic Fibrosis Foundation Therapeutics for USD3.3 Billion 18
Royalty Pharma Completes Acquisition of Royalties on Alogliptin and Priligy from Forest Labs for USD415 Million 20
Royalty Pharma Acquires Additional Stake In Tecfidera, Oral Multiple Sclerosis Drug, For US$510 Million 21
Royalty Pharma Acquires Ibrutinib Royalty Rights From Quest Diagnostics For US$485 Million 22
Royalty Pharma Completes Acquisition Of Royalty Agreement For Vosaroxin From Sunesis Pharma For US$25 Million 23
Royalty Pharma Acquires BG-12 And Fumaderm From Fumapharm For US$761 Million 25
Avillion Secures Funds from Royalty Pharma 26
Aisling Capital And Clarus Ventures Acquire 20% Of Royalty Interest In Ibrutinib From Royalty Pharma 27
Immunomedics to Raise USD75 Million in Private Placement of Shares 28
RP Management LLC, Key Competitors 30
RP Management LLC, Key Employees 31

List of Figures
RP Management LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
RP Management LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
RP Management LLC, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[RP Management LLC:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Momina Krepost (5MR):企業概要、財務及び戦略的SWOT分析
    Summary Momina Krepost is a medical equipment company. The company manufactures and sells single use medical devices for the healthcare industry. Its products include syringes, injection needles for single use, sets, tubes, catheter, urine collection bags, plastic throat pallet, gynecological plasti …
  • Beckman Coulter, Inc.:企業の戦略的SWOT分析
    Beckman Coulter, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Dong-A Socio Holdings Co Ltd (000640):製薬・医療:M&Aディール及び事業提携情報
    Summary Dong-A Socio Holdings Co Ltd (Dong-A Socio Holdings), formerly Dong-A Pharmaceutical Co., Ltd., offers business management services. It is a subsidiary of Dong-A Socio Group. It operates in various markets such as pharmaceuticals, food and beverages, logistics, IT, and materials. The group f …
  • United Technologies Corporation:企業の戦略、SWOT、動向分析
    The report is a comprehensive, strategic resource on United Technologies Corporation providing key insights, analysis & information on the company. The initial sections provide a snapshot & overview on the business operations & market positioning of the company while the SWOT framework analyzes the …
  • GungHo Online Entertainment, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' GungHo Online Entertainment, In …
  • Ringier AG:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Ringier AG Mergers and Acquisit …
  • Development Center for Biotechnology:製薬・医療:M&Aディール及び事業提携情報
    Summary Development Center for Biotechnology (DCB) is a non profit organization that offers support to biotechnology and pharmaceutical companies. The organization develops biotech industry through its cooperation and industrialization, key technologies, infrastructure building, research and develop …
  • Haldia Petrochemicals Limited:企業の戦略的SWOT分析
    Haldia Petrochemicals Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Bhansali Engineering Polymers Limited (BEPL):企業財務及び戦略的SWOT分析
    Summary Bhansali Engineering Polymers Limited (BEPL) is a petrochemical company that manufactures and markets acrylonitrile butadiene styrene. The company offers products which include general ABS, ABS-GF or SAN-GF, extrusion ABS, flame retardant ABS, PC or ABS alloys, PMMA-ABS, PVC modifier, SAN re …
  • Verisk Analytics, Inc.:企業のM&A・提携・投資分析
    Verisk Analytics, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Verisk Analytics, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • American TonerServ Corp.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' American TonerServ Corp. Merger …
  • Asplundh Tree Expert LLC:企業の戦略的SWOT分析
    Asplundh Tree Expert LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Cell Culture Technologies LLC(製薬・医療分野):企業M&A動向
    Summary Cell Culture Technologies LLC (Cell Culture) is a biotechnology company. The company provides mammalian cell culture systems for the production of recombinant proteins, monoclonal antibodies, and viral particles in protein. Its products include chomaster, turbodoma, invitrus, hektor, spodomi …
  • Zhejiang Sanlux Rubber Co., Ltd. (002224):企業の財務及び戦略的SWOT分析
    Summary Zhejiang Sanlux Rubber Co., Ltd. (Sanlux) is a chemical company that manufactures rubber belts such as classical wrapped V-belts, cogged V-belts and specific transmission V-belts. The company offers products such as wedge wrapped v-belt, classical wrapped v-belt, banded wedge v-belt, banded …
  • Investec Limited (INL):企業の財務及び戦略的SWOT分析
    Summary Investec Limited (Investec) is a financial consulting company that provides deposit and lending services. The company conducts business through the divisions such as asset management, wealth and investment, property, private banking, investment banking and capital markets. It provides asset …
  • Tata Chemicals Limited (TATACHEM):企業概要、財務及び戦略的SWOT分析
    Summary Tata Chemicals Limited (TCL) is a holding company. The company offers living, industry and farm essential chemicals. Its products include consumer salt, pulses, water purifier, soda ash, allied chemicals, industrial salt, sodium bicarbonate, cement, fertilizers, pesticides, specialty nutrien …
  • Sigma-Tau SpA:企業のM&A・提携動向(医療分野)
    Summary Sigma-Tau SpA (Sigma-Tau) is one of the key Italian pharmaceutical companies. It offers products across therapeutic areas such as, cardiology and metabolic, gastroenterology, respiratory, pneumology, infectious diseases, urology, rheumatology, osteoporosis, neurology and oncology. The compan …
  • Imagination Technologies Group Plc:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Imagination Technologies Group …
  • BioPorto Diagnostics A/S (formerly AntibodyShop A/S):企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' BioPorto Diagnostics A/S (forme …
  • Smith & Williamson Holdings Ltd:企業の戦略的SWOT分析
    Smith & Williamson Holdings Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆